Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Phase II Clinical Study of Iruplinalkib Combined With Bevacizumab as Neoadjuvant Therapy for ALK-positive Non-small Cell Lung Cancer.

NCT07870733 is registered in ClinicalTrials.gov with Shanghai Pulmonary Hospital, Shanghai, China as lead sponsor.

NCT NCT07870733
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07870733 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Phase II Clinical Study of Iruplinalkib Combined With Bevacizumab as Neoadjuvant Therapy for ALK-positive Non-small Cell Lung Cancer.
Lead sponsor
Shanghai Pulmonary Hospital, Shanghai, China
Phase
Not applicable
Overall status
Not yet recruiting
Start date
September 15, 2026
Completion date
July 1, 2031
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

alk, neoadjuvant therapy, nsclc